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See Article, pages 655–666The hepatitis C virus comprises 6 genotypes and more
than 100 subtypes. While diﬀerences in the virologic
response rates to peginterferon alfa plus ribavirin com-
bination therapy are well established, less evidence has
been accumulated regarding whether HCV genotypes
are associated with diﬀerences in the natural course of
disease. No clinically relevant diﬀerences with respect
to symptoms and extrahepatitic manifestations of
chronic hepatitis C according to HCV genotypes are
reported. The published data on the impact of HCV
genotypes on ﬁbrosis progression rates, development
of cirrhosis, and the risk for hepatocellular carcinoma
are somewhat conﬂicting leading to the overall percep-
tion that clinically relevant diﬀerences are non-existant.
Studies on the possible association of HCV genotype
with the ﬁbrosis progression rates are complicated by
confounding factors, e.g. by the fact that HCV-1b
infected patients in several regions are older than
HCV-1a and HCV-3a infected patients and typically
show substantial diﬀerences with respect to transmission
risk factors [1–3].
The study by Bochud et al. [4] is one of the largest
data sets on the association of HCV genotypes and
ﬁbrosis progression rates. The data of this study indicate
a faster ﬁbrosis progression rate in patients infected with
HCV genotype 3 compared with patients infected with
HCV genotype 1, supporting some previous smaller
studies which showed a similar trend [5,6].0168-8278/$36.00  2009 European Association for the Study of the Liver.
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E-mail address: Zeuzem@em.uni-frankfurt.deThe methodology of the study by Bochud et al. is
sound since the authors used both a stage-constant
and a stage-speciﬁc estimation of ﬁbrosis progression
rates according to diﬀerent HCV genotypes, together
with cumulative incidence curves. The concordant
observation that HCV genotype 3 was associated with
accelerated ﬁbrosis both in stage-speciﬁc and stage-con-
stant ﬁbrosis rate estimates in a large cohort of well-
characterized patients make the data appear robust. A
possible limitation of the study as outlined in the discus-
sion of the paper [4] is the fact that the estimated dura-
tion of infection was based on the ﬁrst event at risk,
which may not be accurate. Furthermore, biopsy speci-
mens were not read by a central pathologist and the
authors cannot rule out other confounding factors, e.g.
that patients infected with HCV genotype 3 infection
may have had a higher exposure to liver-toxic agents
beyond alcohol (e.g. continuous use of illicit drugs).
Thus, some concerns remain as in most studies with a
cross-sectional design, and the data should be conﬁrmed
in other cohorts and if at all possible in prospectively
designed trials.
What are the practical consequences if indeed ﬁbrosis
progression rates are faster in patients infected with
HCV genotype 3 ? First, comprehensive counselling of
patients with respect to proven (alcohol consumption)
or suspected concomitant factors (overweight, iron over-
load) is mandatory. Second, reluctance to defer or delay
antiviral therapy may not be appropriate. Generally,
sustained virologic response rates in patients chronically
infected with HCV genotype 3 are high. Combination
therapy with peginterferon alfa and ribavirin for 24
weeks achieves sustained virologic response rates of
70–80% [7,8]. In patients with low baseline viral load
(<800,000 IU/mL) and a rapid virologic responsePublished by Elsevier B.V. All rights reserved.
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out compromising SVR rates [9]. However, in patients
with high baseline viral load (>800,000 IU/mL) and/or
without a rapid virologic response virologic relapse rates
after 24 weeks of combination therapy are high [9,10].
Retrospective analyses suggest that this subpopulation
may beneﬁt from 48 weeks of combination therapy
including higher doses of ribavirin (1000–1200 mg/day)
[8,11]. Prospective trials are ongoing to ﬁnally answer
this open question. No study has yet speciﬁcally studied
treatment success in HCV genotype 3-infected patients
with liver cirrhosis, but clinical experience shows that
SVR is diﬃcult to achieve in this population.
Due to marked improvement in SVR rates for HCV-1
infected patients treated with peginterferon alfa, ribavi-
rin, and a NS3 serine protease inhibitor [12–14], treat-
ment is currently delayed in many patients to await
approval of these speciﬁcally targeted antiviral therapies
(STAT-C drugs). All physicians treating patients with
chronic hepatitis C, however, should be reminded that
the clinically most advanced protease inhibitors telapre-
vir and boceprevir are mainly active against HCV geno-
types 1 (and 2) and less active against HCV genotypes 3
and 4 [15,16]. Similarly, non-nucleoside polymerase
inhibitors are generally active against HCV-1 isolates
[17]. Activity against HCV-3 isolates has yet been
documented only for nucleoside polymerase inhibitors
(e.g. R7128) and cyclophilin inhibitors (e.g. Debio-025)
[18,19]. Taken together, combination of peginterferon
alfa and ribavirin could remain the key treatment option
for patients infected with HCV genotype 3 in the years to
come. If indeed ﬁbrosis progression in patients infected
with HCV genotype 3 is faster than in HCV-1 infected
patients, waiting for new treatment options should be
strongly discouraged in this patient population.
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